SCHEMBL19167342

SCHEMBL19167342

c1ccc(-c2cc(-c3ccc(-c4ccc5ccc6cccc7ccc4c5c67)cc3)nc(-c3ccccc3-c3ccccn3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.43
TSHR P16473 4/20 0.43
MAPK1 P28482 2/20 0.43
GRM5 P41594 5/20 0.40
SMN1; SMN2 Q16637 6/20 0.39
KDM4E B2RXH2 5/20 0.39
MAPT P10636 5/20 0.39
TP53 P04637 5/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
PKM P14618 4/20 0.39
NPC1 O15118 4/20 0.39
LMNA P02545 3/20 0.39
KLF5 Q13887 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RAB9A P51151 4/20 0.39
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19168071 0.94 HSD17B10 (0.40) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19167665 0.94 HSD17B10 (0.40) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19166294 0.94 HSD17B10 (0.44) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19168474 0.93 HSD17B10 (0.39) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19166991 0.93 HSD17B10 (0.44) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19167409 0.92 KDM4E (0.41) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19167646 0.90 HPGD (0.42) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19168095 0.90 HPGD (0.42) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19167002 0.90 HPGD (0.42) HSD17B10TSHRMAPK1GRM5SMN1; SMN2
SCHEMBL19167006 0.90 HSD17B10 (0.46) HSD17B10TSHRMAPK1GRM5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10797244-B2 Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2020-10-06 US disclosed
US-20170213982-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-07-27 US disclosed
US-20170213982-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10797244-B2 Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device RER1, RBM12, H1-2 HSD17B10 2839/4885TSHR 1590/4885MAPK1 500/4885
US-20170213982-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE RER1, RBM12, H1-2 HSD17B10 2839/4885TSHR 1590/4885MAPK1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.